BMY Q2 revenue $11.2B, GAAP EPS $0.99, non-GAAP $1.75; cuts FY guidance on Revlimid decline

BRISTOL MYERS SQUIBB CO

2023-Q2 EPS reported $2.06 revenue$22,563,000,000

Q2 revenue $11.2B, down 6% YoY (5% ex-FX); GAAP EPS $0.99 (up 50% YoY), non-GAAP EPS $1.75 (down 9% YoY).
Revlimid decline faster than expected; FY guidance revised: revenue low single-digit decline, GAAP EPS $3.72-$4.02, non-GAAP EPS $7.35-$7.65.
In-line and new product portfolio grew 4% YoY; pipeline and regulatory milestones advanced.
Announced $4B accelerated share repurchase agreement expected to execute in Q3 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

BRISTOL MYERS SQUIBB CO reported the second quarter of 2023 results: revenue $11.2 Billion, EPS $0.99. Guidance lowered.

Period: the second quarter of 2023
Revenue: $11.2 Billion
EPS: $0.99
Guidance: lowered
Result: reported results

Exact text from the filing

Bristol Myers Squibb Reports Second Quarter Financial Results for 2023 • Reports Second Quarter Revenues of $11.2 Billion • Posts Second Quarter GAAP Earnings Per Share of $0.99 and Non-GAAP EPS of $1.75;

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

BRISTOL MYERS SQUIBB CO filing history →

Source: SEC EDGAR

accession 0000014272-23-000150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.